The Liposcale® test is an advanced lipoprotein test based on 2D Nuclear Magnetic Resonance (NMR) that determines the size and number of lipoprotein particles for the main types (VLDL, LDL and HDL) and also each subtype size and concentration, determining its categorization by nine sizes: large, medium and small particles of each main type.
The Liposcale® test provides much more accurate and precise analytical results than other currently used methods thanks to 2D Nuclear Magnetic Resonance spectroscopy. It is also technologically innovative because it measures directly the physical size of the particles under a non-destructive sample’s method with all values and measurements being highly reproducible.
The use of lipoprotein particles, to identify or control lipid disease evolution, shown more accuracy in Cardiovascular Risk (CVR) evaluation than the measurement of LDL cholesterol levels.
The Liposcale® medical software algorithm has been developed inside the University Rovira i Virgili (Tarragona, Spain) and is patented and CE marked.
The test generates the LIPOSCALE® Report that contains, on top of the regular values (Total cholesterol, c-LDL, c-HDL and Triglycerides) recommended nowadays:
- The size and number determination of each principal lipoprotein subclass related to cardiovascular disease risk and its deviation regarding normality values.
- The particle values, in digital format, to be integrated in some other personalized reports, for patient evaluation and follow up.
- A specific patient lipid map for better disease classification with a draw of all integrated parameters at risk.
- The patient correlation with the normal or abnormal population data./li>
The test, that could be used as clinical or investigational tool, is fully available in Spain since January 2017. The process works under a central lab model that could be also worldwide implemented. The www.report.liposcale.com platform was developed in that sense for sample trackability and for obtaining the LIPOSCALE® report in a secure data protected environment.
What is more relevant in cardiac risk evaluation, on top of the concentration of LDL cholesterol, is the number and size of lipoprotein particles transporting this cholesterol.
The smaller LDL particles (p-LDL) can more readily enter in the arterial wall, thus favouring the cholesterol accumulation in the wall. The distribution pattern with and increased number of small LDL particles is characteristic of several pathologies, such atherogenic metabolic disorders, type 2 diabetes (T2DM) or chronic kidney disease (CKD), which are most prone to experience cardiovascular episodes. Therefore, there is a need to provide doctors with better tools for a real cardiovascular risk evaluation.
The phenotypic characterization of LDL particles with smallest and, therefore, the most particles has a highest cardiovascular risk. In this regard, several clinical guides in EU or USA appeared in 2016 are recognizing this fact and recommend medical practitioners to use the small LDL particles number as much more accurate parameter to properly evaluate during follow-up the efficacy for hypolipemic treatments and, in consequence, determining the residual risk for cardiovascular disease more accurately than c-LDL measurement. The last January 2017, the published consensus from AACE/ACE recommend different hypolipemic agents, depending on each dislipemia profile, and its associated therapeutic objective, specifically in the sense of controlling and decreasing the p-LDL.
LIPOSCALE® test can be used both in the clinical and research fields. Cardiology, Endocrinology, Nephrology, Angiology and Vascular surgery, Neurology or Lipidology are the specialities that could benefit from diagnosis management, risk evaluation perspective, therapeutic efficacy and patient follow-up.
Market implementation is ongoing in several corporate clients in Spain. Commercial model as central lab is available in Spain through several labs. The commercial activity is on place since January 2017.
Still ongoing additional clinical validations for the cardiovascular risk evaluation improvement through several trials in selected populations:
- LIPOLAB study, CV Risk prevalence in a non diseased working population.
- ESCARVAL prevention study, trough INCLIVA.
Liposcale® has been used in several investigational areas for different purposes: Polycystic ovary syndrome, nutritional interventions, Atherogenic Dislipemia, T2DM, general population profiling, SLE, LAL-D, rheumatoid arthritis, CKD chronic kidney disease, among others
BiosferTeslab the initial developer is a continuous research partner in Liposcale® product range but also other future metabolomic product tests.
University Rovira i Virgili in Tarragona, Spain, provided the technical environment and proper structure during Liposcale creation and still involved in future NMR developments.
INCLIVA Foundation, Spanish Atherosclerosis Society and Spanish Nephology Society are research partners working with LIPOSCALE® products.
For more information you can visit the web: Test de Lipoproteínas